Recent update on biological activities and pharmacological actions of liraglutide.

about

Recent update on biological activities and pharmacological actions of liraglutide.

Item

http://www.wikidata.org/entity/Q41290574

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Recent update on biological activities and pharmacological actions of liraglutide.

@en

type

Item

label

Recent update on biological activities and pharmacological actions of liraglutide.

@en

prefLabel

Recent update on biological activities and pharmacological actions of liraglutide.

@en

P1476

Recent update on biological activities and pharmacological actions of liraglutide

@en

P2093

Anurag Mishra

http://www.w3.org/2001/XMLSchema#string

Gaurav Gupta

http://www.w3.org/2001/XMLSchema#string

Juhi Tiwari

http://www.w3.org/2001/XMLSchema#string

Kavita Pabreja

http://www.w3.org/2001/XMLSchema#string

Rajiv Dahiya

http://www.w3.org/2001/XMLSchema#string

Rakesh Kumar Sharma

http://www.w3.org/2001/XMLSchema#string

P2860

Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats

A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges

Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro.

Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice

Downregulation of miR-139-5p contributes to the antiapoptotic effect of liraglutide on the diabetic rat pancreas and INS-1 cells by targeting IRS1.

Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study).

Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways.

Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment.

Liraglutide attenuates the osteoblastic differentiation of MC3T3‑E1 cells by modulating AMPK/mTOR signaling

Liraglutide Enhances the Efficacy of Human Mesenchymal Stem Cells in Preserving Islet β-cell Function in Severe Non-obese Diabetic Mice.

P304

742-747

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.17179/EXCLI2017-323

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

K Dua

P577

2017-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28827989

http://www.w3.org/2001/XMLSchema#string

P932

5547392

http://www.w3.org/2001/XMLSchema#string